Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
- 3 May 2007
- journal article
- clinical trial
- Published by Elsevier in The Lancet Neurology
- Vol. 6 (6) , 501-512
- https://doi.org/10.1016/s1474-4422(07)70109-6
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's diseaseCurrent Medical Research and Opinion, 2006
- Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year periodCurrent Medical Research and Opinion, 2005
- Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variationJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's diseaseNeurobiology of Aging, 2005
- Apolipoprotein E: a major piece in the Alzheimer's disease puzzleJournal of Cellular and Molecular Medicine, 2001
- Imaging of Nicotinic and Muscarinic Receptors in Alzheimer's Disease: Effect of Tacrine TreatmentDementia and Geriatric Cognitive Disorders, 1997
- The Neuropsychiatric InventoryNeurology, 1994
- Genuine memory deficits in dementiaDevelopmental Neuropsychology, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982